MBAL Serdika Ltd.
- Address
- lock Available on a paid plan
MBAL Serdika Ltd. - Advanced Oncology Research Center
MBAL Serdika Ltd. is a prominent clinical research facility specializing in advanced oncology trials, with particular expertise in thoracic malignancies and solid tumors. The center demonstrates significant capabilities in conducting complex Phase III studies evaluating novel immunotherapies, targeted agents, and combination treatment strategies for various cancer types.
- Non-Small Cell Lung Cancer (NSCLC) studies including adjuvant therapy, maintenance treatment, and novel targeted therapies for specific genetic mutations (EGFR, ALK, HER2, KRAS G12C)
- Advanced breast cancer research focusing on hormone receptor-positive, HER2-negative disease and ESR1 mutations with CDK4/6 inhibitor combinations
- Gastrointestinal oncology trials including gastric, gastroesophageal junction, and colorectal cancers with biomarker-selected populations
- Small Cell Lung Cancer (SCLC) investigations and ovarian cancer research with novel antibody-drug conjugates
The center has extensive experience with checkpoint inhibitors (pembrolizumab, nivolumab, durvalumab, cemiplimab) and demonstrates proficiency in managing studies involving biomarker-driven patient selection including PD-L1 expression, FGFR2b overexpression, and various oncogenic driver mutations. MBAL Serdika Ltd. also participates in innovative research addressing cancer cachexia and chronic rhinosinusitis with nasal polyps, showcasing capabilities beyond traditional oncology. The facility's portfolio includes rollover studies and long-term safety evaluations, reflecting commitment to comprehensive patient care and sustained follow-up in clinical research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 5 therapeutic areas and 15 of 70 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 70 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Amgen Inc.1active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.5trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MBAL Serdika Ltd.
lock Showing 1 of 24 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 70 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 6 | Unknown | 2020-12-18 | 2025-04-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.